Kutse

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.22.2025 The World Health Organization (WHO) presents its compliments to Member States and Associate Members and has the pleasure of announcing that the 48th Expert Committee on Drug Dependence (ECDD) will meet from 20 to 22 October 2025 in Geneva, Switzerland. Given that WHO Expert Committee meetings are of a closed nature, this letter serves to notify Member ... States of the agenda of the 48th ECDD, which is in the Annex I file, attached for reference. WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make recommendations to the UN Secretary-General on the need for and level of international control of psychoactive substances based on the advice of its independent scientific advisory body, the ECDD. To assess whether or not a psychoactive substance should be placed under international control, the ECDD convenes annually to review the potential of that substance to cause dependence, abuse and harm to health, as well as any therapeutic applications. In order to perform this review and make evidence-based decisions, the ECDD conducts medical, scientific, and public health evaluations of the selected psychoactive substances using the best available information. Although the meetings are of a closed nature, Member States and Associate Members are invited to contribute to the ECDD review process by joining the 48th ECDD Information Session on 20 October 2025. The Information Session will be held virtually and allow interested parties to learn about present and future activities of the ECDD Secretariat, and to present information concerning substances under review to the 48th Expert Committee for consideration in its deliberations. Registration information will be made available on the ECDD website in due course: https://www.who.int/news-room/events/detail/2025/10/20/default-calendar/forty-eighth- expert-committee-on-drug-dependence. As in the past and in line with the publication “Guidance on the WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6), 1 Member States and Associate Members can also contribute to the ECDD review process by providing up to date and accurate information concerning the substances under review in advance of the meeting. For this purpose, and as per previous practice, a questionnaire will be sent to Member States and Associate Members to gather country information on the legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation. 1 https://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=90. ... ENCLS.: (2)  Page 2 C.L.22.2025 ... Annex II to this Circular Letter contains a list of national focal points officially designated by Member States and Associate Members in previous years who provide country information to the ECDD through the Member States questionnaire referred to above. If the focal point information requires changes or amendments, Member States and Associate Members are invited to inform the WHO ECDD Secretariat by email to [email protected] by 18 July 2025 with the subject “48ECDD Focal Point: (Country Name)”. If the individual on the list is still the official focal point for completing the ECDD Member State questionnaire this year and if no additions or amendments to focal point details are made by 18 July 2025, the focal point from the list will be given further instructions and direct access to online questionnaires by the WHO Secretariat. Results of the questionnaires will be prepared as a report as part of the 48th ECDD substance review process. In addition to the questionnaire, Member States and Associate Members are also encouraged to provide any additional relevant information (unpublished or published) on substances to be reviewed by the 48th ECDD by emailing [email protected] with the subject “Ref: C.L.22.2025”. All recommendations made by the 47th ECDD, held in October 2024, were accepted by the 68th UN Commission on Narcotic Drugs and all technical reports and recommendations made by the ECDD are available online through the recently launched ECDD Information Repository (https://ecddrepository.org/en). The World Health Organization takes this opportunity to renew to Member States and Associate Members the assurance of its highest consideration. GENEVA, 11 July 2025  48th WHO EXPERT COMMITTEE ON DRUG DEPENDENCE Provisional Agenda ---- Information Meeting (Virtual) 20 October 2025 10:00-13:00 CEST 1. Welcome and opening of the meeting 2. WHO presentations 2.1 Expert Committee on Drug Dependence 2.2 Science Division 2.3 Gender, Equity, and Human Rights 2.4 Traditional medicine 3. Presentations and statements from participants  48th WHO EXPERT COMMITTEE ON DRUG DEPENDENCE Geneva, Switzerland Provisional Agenda ---- Closed Session 20–22 October 2025 1. Procedural matters and updates 1.1 Opening of meeting and welcoming remarks 1.2 Introduction of participants 1.3 Statement of confidentiality 1.4 Declarations of interest 1.5 Election of Chair, Vice-Chair, and Rapporteur 1.6 Adoption of agenda 2. Updates on priorities from international agencies 2.1 Briefings from international agencies on their work on the public health dimension of the world drug problem 2.1.1 WHO 2.1.2 UNODC 2.1.3 INCB 2.2 Updates on ECDD meeting recommendations and outcomes 2.2.1 Recommendations and outcomes of the 47th ECDD 2.2.2 Updates on substance surveillance 3. Critical reviews: Recommendations on the scope of international control 3.1 Coca leaf 1 3.1.1 Coca leaf 3.2 Synthetic cannabinoids 2 3.2.1 MDMB-FUBINACA 3.3 Novel synthetic opioids2 3.3.1 N-pyrrolidino isotonitazene (Isotonitazepyne) 3.3.2 N-Desethyl etonitazene 4. Finalization of meeting report 1 There has been a notification from a Party to the 1961 or the 1971 Convention concerning the scheduling of a substance. 2 Information was brought to WHO’s attention that a substance is clandestinely manufactured, or especially serious risk to public health and society, and of no recognized therapeutic use by any Party. Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Afghanistan Regulation Sector of Pharmaceutical Market and Medical Devices Albania Linda Ternova Specialist Ministry of Health and Social [email protected] Protection, Albania Narcotics, Psychotropics and Chemical Precursors, General Direction of Algeria Ghrieb Houria Doctor [email protected] Pharmacy and Health Equipment, Algerian Health Ministry Department of Health Resources and Andorra Carla Lobaco Valls Technical Officer [email protected] Medicines Department of Health Resources and Andorra Carme Pallarés Papaseit [email protected] Medicines General Director, National Institute for Angola Ana Da Conceição Mamede Ministry of Health [email protected] combating Drugs Antigua and Barbuda Director of Surveillance of Substances Subject to Special Control Argentina G. Rebaldería Pharmacist [email protected] Argentinian Ministry of Health Armenia Hasmik Martirosyan Armenian Ministry of Health [email protected] Narcotics Control Section Office of Drug Control Australia [email protected] 7/10/2024 Australian Government Department of Health and Aged Care Australia [email protected] Section VI, Department 6 Federal Ministry of Social Affairs, Austria Raphael Bayer Head of Division Health, Care and Consumer [email protected] Protection Azerbaijan Telman Suleyman Oglu Mammadhassanov [email protected] Bahamas Bahrain Samar Yousef Salem Senior Pharmacist Ministry of Health [email protected] Health Services Division, Bangladesh Habibur Rahman Khan Additional Secretary [email protected] Ministry of Health & Family Welfare Barbados Lindsay Bynoe Assistant Director for Drug Regulation Ministry of Health [email protected] Belarus Aleksey Kralko Ministry of Health [email protected] Epidemiology and Public Health, Head of Unit illicit Drugs, Reitox National Belgium Lies Gremeaux Sciensano, [email protected] Focal Point Ministry of Health Belize State-certified Pharmacist, Head of Pharmaceutical Establishments Benin Saturnin Bognon [email protected] Pharmaceutical Establishments Department Department Department of Public Health, Ministry Bhutan Dil Kumar Subba [email protected] of Health Permanente Representative of the Bolivia (Plurinational State of) H.E. Amb. Maira Mariela Macdonal [email protected]; [email protected] 7/27/2024 Plurinational State of Bolivia Bosnia and Herzegovina [email protected]; [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Department for Health, Ministr of the Bosnia and Herzegovina Sabina Šahman Civill Affairs of Bosnia and [email protected] Herzegovina Department of Clinical Services, Botswana Vivian Sebako Chief Pharmacist [email protected] Ministry of Health and Wellness Management of Controlled Products GPCON/GGMON/DIMON/ANVISA Controlled Substances Office Brazil Renata de Morais Souza, Moema Luisa Silva Macedo Manager [email protected] Brazilian Health Regulatory Agency – ANVISA International Affairs Office, Brazilian Brazil Natalia Jorge e Costa Health Regulatory Agency - ANVISA, [email protected] AINTE/ GADIP/ANVISA Department of Pharmaceutical Brunei Darussalam Hajah Zanatul ‘Aini Haji Zainin (Ms) Acting Director of Pharmaceutical Services [email protected] Services, Ministry of Health Department Health Promotion and Bulgaria Slaveyka Nikolova Chief Expert at the Health Promotion Prophylaxis of the Diseases and [email protected] Addictions Directorate Mental Health and Addiction Head of the National Focus Center Bulgaria Alexander Panayotov Prevention Directorate, National [email protected] Department Center for Public Health and Analysis Burkina Faso [email protected] Burundi Israël Nimubona [email protected] Commission for the Coordination of Cabo Verde Raquel Lopes Alcohol and Other Drugs, Ministerio [email protected] 8/30/2024 da Saude e da Seguranca Social Department of Mental and Substance Cambodia Chhit Sophal Director [email protected] Abuse, Ministry of Health Cameroon Ketchozo Loko Wilfried [email protected] International Relations Unit, Office of Drug Policy and Science, Controlled Canada [email protected] 4/26/2024 Substances Directorate, Health Canada, Government of Canada Central African Republic Chad Haoua Haroun Saker Deputy Director of Pharmacy and Medicine Ministry of Public Health [email protected] Department of Mental Chile Javiera Erazo Leiva Advisor [email protected] Health/DIPRECE, Ministry of Health China Zhendong HUA Deputy Director National Narcotics Laboratory [email protected] Office of National Narcotics Control China Yan ZHENG Official [email protected] Commission China Peng XU Senior Expert National Narcotics Laboratory [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Observatorio de Drogas de Colombia Dirección de Políticas de Drogas y Colombia Oscar Ricardo Santana [email protected]; [email protected] 7/16/2024 Actividades Relacionadas Ministerio de Justicia y del Derecho Dirección de Promoción y Prevención Coordinadora del Grupo Convivencia Social y Colombia Nubia Esperanza Bautista   – Ministerio de Salud y Protección [email protected] Ciudadanía Social Coordinador Grupo Interno de Trabajo de [email protected]; Colombia Germán Andrés Calderón Velásquez Ministerio de Relaciones Exteriores Asuntos Relacionados con las Drogas [email protected] Comoros Cook Islands Tereapii Uka Central Policy and Planning Office [email protected] Costa Rica Marchena Vasquez [email protected] Côte d'Ivoire Ernest Zotoua [email protected] Head of National Information Unit in the Croatia Lidija Vugrinec Field of Drugs and Behavioural Addictions Croation Institute of Public Health [email protected] 8/30/2024 and Internal Relations Department Cuba Pharmaceutical Services, Ministry of Cyprus John Kkolos Pharmacist [email protected] Health Inspectorate Department, Narcotic Czechia Vlastimil Brandejs and Psychotropic Substances [email protected] Ministry of Health Democratic People's Republic of Korea Kim Jong Guk Democratic Republic of the Congo Ghislaine Mbelu Kanyunya [email protected] Head of Focal Point, Prevention, Denmark Kari Gragaasen Chief Consultant [email protected] National Board of Health Djibouti Ministry of Health, Wellness and New Dominica Laura Esprit Chief Medical Office [email protected] Health Investment Ministry of Health, Wellness and New Dominica Anna Royer-Edmund Chief Pharmacist [email protected] Health Investment Dominican Republic [email protected] General Directorate of Medicines, Head of the Assistive Technology Dominican Republic Francisca Dalia Castillo Sanchez Food and Health Products [email protected] Department (DIGEMAPS), Ministry of Public Health Director nacional de Estrategias de Salud Mental Y Fenomeno Ecuador Gabriel Ordonez Guzman Prevencion Y Control para Enfermedades no [email protected] 7/24/2024 Socioeconomico de las Drogas Transmisibles Egypt Dr Samah Abdeleazik Kandil Ministry of Health and Population [email protected]; [email protected] 7/16/2024 Focal Point of the Ministry of Health of El Health Technology Department, El Salvador José Mauricio Bermúdez Recinos [email protected] Salvador Ministry of Health Equatorial Guinea Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Eritrea Michael Girmay Haile [email protected] Inspector of pharmacovigilance, drugs and State Agency of Medicines, Ministry of Estonia Olga Kamp [email protected] psychotropic substances, and the precursors Health Eswatini Ethiopia Baharu Zewdie Moya [email protected] Pharmaceutical & Biomedical Fiji Ilisabeta May Pesamino Chief Pharmacist Services/Ministry of Health & Medical [email protected] Services Finnish Medicines Agency, Ministry of Finland Katja Pihlainen [email protected] Health Regulation of narcotics and psychotropic substances, France Luciano Amato Acting Head of Department National Agency for the Safety of [email protected] Medicines and Health Products Directorate of Medicines and Pharmacy Gabon Okouyi Ndakissa [email protected] Ministry of Health Gambia Division of Legal Circulation of Narcotic Drugs, LEPL State Regulation Agency for Medical Activities Georgia Ekaterine Paposhvili Senior Specialist [email protected] Ministry of Labour, Health and Social Affairs of Georgia Division 122 - Narcotics Law, Traffic in Narcotics, International Narcotic Drug Germany Annette Hinze Affairs [email protected] Federal Ministry of Health Pharmaceutical Services, Ministry of Ghana Martha Gyansa-Lutterodt Director [email protected] Health Head of General Directorate of Public Greece Dr Foteini Koulouri Hellenic Ministry of Health [email protected] ; [email protected] 7/16/2024 Health and Quality of Life Psychiatrist, Programs Implementation OKANA - Organisation Against Drugs Greece Avgerinos Nikolaos [email protected] ; [email protected] Director Greece Greece Ms Anastasia Petroulia Legal Advisor to the Minister of Health Hellenic Ministry of Health [email protected]; [email protected] Will also attend the 47th ECDD meeting Grenada Department of Regulation and Control of Guatemala José Miguel Solares Estrada [email protected] 8/30/2024 Related Pharmaceutical Products Section of Psychotropics, Narcotics, Imports Guatemala Alicia Elena Morgan Durán [email protected] 8/30/2024 and Exports Guinea Guinea-Bissau Guyana Haiti Marie Judith Robuste Roche Ministry of Health [email protected] Honduran Institute for the Prevention General Director of the Honduran Institute Honduras Alex Virgilio Santos Moreno of Alcoholism, Drug Addiction and [email protected] for the Prevention of Alcoholism Drug Dependence (IHADFA) Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update EMMI Pharmaceutical and Medical Hungary Tímea Kahlesz Deputy Head of Department [email protected] Technology Department Iceland Bjarni Sigurðsson Ministry of Health [email protected] Department of Psychiatry, National India Dr Anju Dhawan Professor and Head Drug Dependence Treatment Centre, [email protected] 7/24/2024 All India Institute of Medical Sciences Director of Pharmaceutical Production and Directorate General of Pharmaceutical Indonesia Agusdini Banun Saptaningsih [email protected] Distribution Care and Medical Devices, Iran (Islamic Republic of) Mina Azhoogh [email protected] Iraq Emad Abdulrazzaq Abdulghani Ministry of Health [email protected] Ireland Conor Brennan Department of Health [email protected] Ireland Alan Bell Department of Health [email protected] Israel Paola Rosca Head of the Addiction Treatment Department Ministry of Health [email protected] The Competent Authority for Narcotics, Psychotropics and Israel Tal Lavy [email protected] Precursors Pharmaceutical Administration Ministry of Health - Directorate Italy Pietro Canuzzi Head of Office 7, Central Narcotic Office [email protected] 7/26/2024 general of Health Prevention Jamaica Dr Jacquiline Bisasor McKenzie Chief Medical Officer Ministry of Health & Wellness [email protected] 7/5/2024 National Council on Drug Abuse Jamaica Ms Uki Atkinson Research Analyst [email protected] 7/5/2024 (NCDA) Compliance and Narcotics Division, Japan Pharmaceutical Safety and [email protected] Environmental Health Bureau Head of Narcotics, Psychotropic Substances and Chemical Precursors Jordan Malak AlMahirah [email protected] Department, Jordan Food and Drug Administration Republican Scientific and Practical Kazakhstan Prilutskaya Marina [email protected] Center of Mental Health Kenya Anthony Toroitich [email protected] Kenya Simon Njuguna [email protected] Ministry of Health and Medical Kiribati Biribo Kararaiti Chief Pharmacist [email protected] Services Control of Licenses for Narcotic Drugs Kuwait Ali Abdulmohsen Jaragh Head and Psychotropic Substances [email protected] 7/24/2024 Department Drug Trafficking Control Department, Kyrgyzstan Kanyshai Damirbek [email protected] Ministry of Foreign Affairs Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Department of Hygiene and Health Lao People's Democratic Republic Khatthanaphone Phandoangsy Head of Health Promotion and Nutrition Unit [email protected] Promotion, Ministry of Health Latvia Linda Veisberga Ministry of Health [email protected] Lebanon Marie-Therese Matar Head of Narcotics Department Ministry of Public Health [email protected] Lesotho Masello Sello [email protected] Liberia Dr. Moses Ziah II Director Mental Health Unit Ministry of Health, Republic of Liberia [email protected]; [email protected] Libya Drug Precursors Control and Risk Assessment Division, Head of Drug Precursors Control and Risk Lithuania Rima Mačiūnienė Drug, Tobacco and Alcohol Control [email protected] Assessment Division Department Luxembourg Alain Origer National Drug Coordinator Ministry of Health [email protected] Madagascar Maximine Ravaoarimanana Director of Pharmacy Laboratories and Traditional Medicine [email protected]; [email protected] Assistant Director of Clinical Services (Mental Malawi Michael Udedi [email protected] Health and Substance Abuse) Pharmaceutical Services Division, Malaysia Rohaida Binti Zakaria Senior Principal Assistant Director [email protected] Ministry of Health Medicine and Therapeutic Goods Division, Maldives Aishath Mohamed Deputy Director General, Pharmaceuticals [email protected] Maldives Food and Drug Authority Mali Mahamadou Ousmane Maiga [email protected] Office of the Superintendence of Public Health, Malta Victor P. Pace [email protected] Department for Health Regulation Marshall Islands Julia Alfred Ministry of Health [email protected] Mauritania Hamoud Fadel Yamohomed Director of Pharmacy and Laboratories Ministry of Health [email protected] Harm Reduction Unit, Ministry of Mauritius Nitish Raj Sokool Officer-in-Charge [email protected] Health and Wellness Mauritius Anil Jhugroo Advisor on Substance Abuse Ministry of Health and Wellness [email protected] COFEPRIS representative, Federal Mexico Angélica Juárez Ramírez Specialized Reviewer Committee for Protection from [email protected] Sanitary Risks Micronesia (Federated States of) Benido Victor [email protected] Pharmacy Inspector, Health Products Monaco Isabelle Kessedjian Head of Division [email protected] Division Mongolia Luvsandagva Purevdorj [email protected] Montenegro Jasna Sekulic Ministry of Health [email protected] Morocco Hassan Elkarimi [email protected] Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Professor of Psychiatry, Rabat Faculty of Medicine, Director of the National Centre on Drug Morocco Jallal Toufiq [email protected] Abuse Prevention, Treatment and Research, Director of the Moroccan Observatory on Drugs and Drugs Addictions Mozambique Flavio Mandlate [email protected] Drug Dependency Treatment and Myanmar Nanda Myo Aung Wan Program Manager/ Consultant Psychiatrist Research Unit, [email protected] Ministry of Health and Sport Namibia Ester Mvula Senior Pharmacist Ministry of Health & Social Services [email protected] Nauru Richard Leona Chief Surgeon Ministry of Health [email protected] Nepal Nutrition, Health Protection and Netherlands Matthijs Geilenkirchen Prevention Department, [email protected] 29 April 2024 Ministry of Health, Welfare and Sport New Zealand Group mail to be cc'ed [email protected] 7/10/2024 Regulatory Practice and Analysis, [email protected] New Zealand Tania Jones Medsafe Confirmed 10/7/24 Nicaragua Karla Vanessa Delgado Martinez Director of Pharmacy Ministry of Health [email protected] Niger Haoua Na Allah Alou [email protected] Nigeria Wosilat Abdulhameed Deputy Director Federal Ministry of Health [email protected] 8/30/2024 Niue North Macedonia Narcotic Drugs Control, Norway Anne S. Onsgård Sagabråten [email protected] Norwegian Medicines Agency Oman Dr. Mohammed Al-Rubaie, [email protected] 7/10/2024 Oman Dr Mahmood Al Abri [email protected] 7/10/2024 Directorate General of Pharmaceutical Oman Affairs and Drug control, [email protected] Ministry of Health Drug Safety Center, Ministry of Oman [email protected] 8/30/2024 Health, Sultanate of Oman Pakistan Rizwan Taj Professor Ministry of Health [email protected] Division of Ancillary Services, Bureau of Hospital and Clinical Palau Clarette Matlab Chief Pharmacist [email protected] Services, Ministry of Health Palau [email protected] Palau Marla Ito [email protected] coordinateur du Programme de Santé Panama Dr Ricardo Goti, Ministère de la Santé du Panama [email protected] 7/16/2024 Mentale Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Program Manager-Non Communicable Public Health Division, National Papua New Guinea Vicky Wari [email protected] Diseases Department of Health Paraguay Blanca Galeano [email protected] 8/30/2024 Paraguay Zaira Francesca Stumpfs Bigarella [email protected] Head of Functional Unit of Controlled DIGEMID – General Directorate of Peru Judith Castañeda Alcántara [email protected] 7/26/2024 Products Medicines, Supplies and Drugs Philippines Information Centre for Drugs and Drug Addiction (CINN) Poland Michał Kidawa Polish Reitox Focal Point [email protected] National Bureau for Drug Prevention Intervention Service for Addictive Behaviours and Addictions Director of Planning and Intervention General Directorate for Intervention Portugal Graça Vilar [email protected] Services Directorate on Addictive Behaviours and Dependencies SICAD Puerto Rico Director of addiction and CL at Hamad Medical Corporation Qatar Majid Ali Al Abdulla Senior Consultant Psychiatrist Deputy Chairman of Mental Health [email protected] Services, Hamad Medical Corporation Narcotics Policy Division of Ministry of Republic of Korea Sang Hun Yeon [email protected] 7/16/2024 Food and Drug Safety Standing Committee on Drugs Control, Republic of Moldova Oleg Costachi [email protected] Agency for Medicines and Medical Devices Romania Camelia Bunaciu Senior Advisor Ministry of Health [email protected] Department for regulation of Russian Federation Alyona Ryzova Deputy Head of the Unit for regulatory and legmedicines and medical devices, [email protected] 7/11/2024 Ministry of Health Rwanda Saint Kitts and Nevis puerto rico Substance Abuse Advisory Council Coordinator of the Substance Abuse Advisory Secretariat, Saint Lucia Charlotte Emmanuel [email protected] Council Secretariat Ministry of Health and Wellness Substance Abuse Advisory Council Secretariat, Saint Lucia Paul Caleb Programme Officer [email protected] Ministry of Health and Wellness Saint Vincent and the Grenadines Samoa Robert Thomsen Assistant Chief Executive Officer HSPQA, Medical and Allied Division [email protected] San Marino Claudio Muccioli Health Authority Director Health Authority [email protected] Sao Tome and Principe Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Administration of controlled preparations, Executive Management for Regulatory Saudi Arabia Adnan Alshammary Affairs, [email protected] Controlled Products Department, Regulatory Affairs Directorate, Drug Sector Pharmaceutical Regulatory Agency, Senegal Moussa DIALLO Pharmacist Inspector [email protected] Ministry of Health and Social Action Monitoring Centre for Drugs and Drug Addiction, Sector for Medicines and Serbia Nataša Savić Medical Devices, Psychoactive [email protected] Controlled Substances and Precursors, Ministry of Health Seychelles Sierra Leone Senior Executive (International Personal Assistant to Director (International Cooperation) Singapore Ong Lay Tin [email protected] 04/07/2024 confiming no changes Cooperation) Public Health Group, Ministry of Health National Monitoring Centre for Drugs, Department of Anti-Drug Strategy Coordination and Drug Monitoring, Slovakia Peter Koreň Reitox National Focal Point [email protected] 04/07/2024 confirming no changes Ministry of Health of the Slovak Republic Directorate of Public Health, Ministry Slovenia Joze Hren Secretary [email protected] of Health National Mental Health Service, Solomon Islands Paul Orotaloa Head of Mental Health Services Ministry of Health and Medical [email protected] Services National Mental Health Service, Solomon Islands Stephen Araitewa Director Mental Health Ministry of Health and Medical [email protected] Services Somalia South Africa MG Molewa Ministry of Health [email protected] Director General of Pharmaceuticals and South Sudan Moses Malual Deng Ministry of Health [email protected] Medical Supplies Head of Department Inspection & Spanish Agency of Medicines and Spain Manuel Ibarra [email protected] Enforcement Medical Products (AEMPS) Narcotics and Psychotropic Substances Area, Pharmaceutical Inspection and Spain Lidia Fernandez Matellano [email protected] Enforcement Department, Spanish Agency of Medicines and Medical Products (AEMPS) Sri Lanka S.C. Wickramasinghe Deputy Director General (NCD) Ministry of Health [email protected] Sudan Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Suriname Ministry of Health and Social Affairs, Division for Public Health and Health Sweden Annika Borg [email protected] 4/8/2024 Care Federal Department of Home Affairs, Federal Office of Public Health, Switzerland Lucien Colliander [email protected] Division of International Affairs, Global Health Section Swissmedic, Swiss Agency for Switzerland Monika Joos Head of Division Narcotics [email protected] Therapeutic Products Mental Health Directorate, Syrian Arab Republic Ahmed Al-Salama [email protected] Ministry of Health Tajikistan Salim Abdulazizov [email protected] Narcotics Control Division (Standards and Regulations Sub-Division), Thailand Sujinart Chantharakul Pharmacist Food and Drug Administration, [email protected] Ministry of Public Health Narcotics Control Division (Standards and Regulations Sub-Division), Thailand Saranya Chavanich Pharmacist Food and Drug Administration, [email protected] Ministry of Public Health Narcotics Control Division Food and Drug Administration, Thailand Korapin Na Ranong Expert on Narcotics Epidemiology [email protected] Ministry of Public Health Narcotics Control Division Food and Drug Administration, Thailand Raththar Benchapalanont Pharmacist Ministry of Public Health Pharmacovigilance and Medicine Control Department, National Timor-Leste Soares Henriques Regulatory Affairs Pharmacist [email protected] Directorate for Pharmaceutical and Medicines, Ministry of Health Centre National de Pharmacovigilance Togo Mouhoudine Yerima [email protected]; [email protected] (CNPV) Tokelau Central Pharmacy and Medical Store, Tonga Melenaite Mahe Principal Pharmacist [email protected] Old Vaiola, Ministry of Health Trinidad and Tobago Anesa Doodnath-Siboo Principal Pharmacist Ministry of Health [email protected] Tunisia Head of Pharmacovigilance and Controlled Turkish Medicines and Medical Türkiye Elif Inci ERGONUL [email protected]; [email protected] 7/24/2024 Substances Department Devices Agency, Ministry of Health Turkmenistan Tuvalu Mental Health and Control of Head of Mental Health and Control of Substance Abuse Division, Uganda Hafsa Lukwata [email protected] Substance Abuse Ministry of Health Annex II: List of focal points designated by Member States in previous years Country Name Focal Point Job title Institution Email Last update Institute of Psychiatry, Forensic Ukraine Deputy Director Psychiatric Examination and Drug [email protected] Monitoring, Institute of Psychiatry of Taras Shevchenko National University of Kyiv, Ukraine Irina Pinchuk Director International Technology Transfer [email protected] Center - Ukraine Head of ISSUP Ukraine National Chapter Institute of Psychiatry, Taras Ukraine Yulia YACHNYK Clinical Psychologist Shevchenko National University of [email protected] Kyiv Product & Precursor Chemicals Drug United Arab Emirates Alia Bin Hussain Head of Regulating Controlled substances Department, [email protected] Ministry of Health and Prevention Addiction and Inclusion Directorate, United Kingdom of Great Britain and Project Manager Drugs Research and Office for Health Improvement & Alberto Oteo [email protected] Northern Ireland Surveillance Disparities, Department of Health and Social Care Pharmaceutical Service Unit, Ministry United Republic of Tanzania Suma Jairo Pharmacist [email protected] of Health Center for Drug Evaluation and Senior Pharmacologist and International United States of America Edward Hawkins research, [email protected] Drug Control Liaison U.S. Food and Drug Administration Coordinator of the Addiction Prevention and Uruguay Lorena Quintana Ministry of Public Health [email protected] 8/2/2024 Treatment Program Head, Department of Inpatient and Uzbekistan Dr Azizbek Khamrakulov Ministry of Health [email protected] Specialized Care Specialized Scientific and Mental Uzbekistan Mr Zarif Ashurov Director [email protected] Health Medical Center Lenakel Health Office, Vanuatu Jerry Iaruel Tafea Provincial Health Administrator [email protected] Ministry of Health Venezuela (Bolivarian Republic of) Viet Nam Mhin Tam Nguyen Regulatory Affair Consultant Ministry of Health [email protected] Yemen Zambia Nita Besa Head Clinical Care Chainama Hospital [email protected] Zimbabwe Eneti Siyame Mental Health Manager Ministry of Health and Child Care [email protected] Saatja: [email protected] Teema: WHO : C.L.22.2025 (48th ECDD) Kuupäev: 2025-07-11 08:29 Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Dear Member States of the World Health Organization, Please find attached, in the six official languages, C.L.22.2025 regarding the 48th ECDD. Should you have questions regarding C.L.22.2025 please send an email to [email protected] Best regards, Department of Governing Bodies World Health Organization ***DO NOT RESPOND TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY***